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In some European settings today, up to 4 out of 5 patients do not receive evidence-
based care despite availability of international high quality guideline recommendations 
addressing the relevant diseases and their management. This is unacceptable in 2018 
because it risks translating into poorer patient outcomes and higher cost of healthcare 
provision. 
Clinical practice guidelines (CPGs) transparently link systematic reviews of the 
evidence to strong and weak recommendations for or against practice that should 
theoretically assist physicians in all aspects of their everyday clinical activities. 
Nonetheless, adherence to clinical guidelines by healthcare professionals is still 
suboptimal or variable across European countries. A low and variable adherence to 
evidence-based recommendations might translate into suboptimal disease 
management and lead to poor patient outcomes. This, in turn, would translate into 
increased expenditures and costs for healthcare systems across the entire continent. 
Recognition of this problem is gaining traction in uro-oncology, with recent examples 
highlighting the overuse of androgen deprivation therapy (ADT) and overuse of 
imaging for localised prostate cancer (PCa); [1] the underreporting of complications in 
robot-assisted radical prostatectomy in PCa patients, resulting in under-diagnosis and 
management of treatment-related side-effects; [2] and the underuse of radiation 
therapy with ADT for high-risk and locally advanced PCa. [3]   
Non-adherence to recommendations is particularly worrying where there is very 
robust, high level of evidence underpinning strong recommendations. For example, 
systematic reviews and individual participant data meta-analyses demonstrated that a 
single immediate post-operative instillation of chemotherapy is well tolerated and 
clinically effective in reducing recurrences in patients with low risk non muscle-invasive 
bladder cancer (NMIBC). [4] As such, the European Association of Urology (EAU) [5] 
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and the National Institute for Clinical and Healthcare Excellence (NICE) [6] 
recommend it’s use in eligible patients. In addition, this approach is considered cost 
effective for the UK’s NHS. [6] Despite this, adherence is generally low, at around 61% 
in the UK as a whole [7] and ranges from 15% to 100% across Scotland. [8-10]. This 
variability indicates suboptimal care across the UK. Small observational studies, using 
historical controls in single centres have demonstrated strategies to increase the use 
of immediate post-operative instillation of chemotherapy in line with CPGs 
recommendations, [11, 12] but these isolated examples are lacking in internal and 
external validity. There are no RCTs comparing implementation interventions with 
concurrent controls to assess which implementation interventions are effective, in 
which situations, and why. 
The reasons for suboptimal adherence to evidence-based recommendations are 
multifactorial and might also reside in the lack of effective measures to improve 
guidelines diffusion and implementation. Moreover, adherence to CPGs might be 
influenced by professional role, keeping up-to-date with current evidence/CPGs, and 
available local facilities. This has been shown in a recent cross-sectional survey of 
Italian urologists, which found that adherence rates to strong EAU guideline 
recommendations on oncologic diseases varied between 55% and 97% and was 
influenced by the working environment. [13] In particular, urologists working in 
university hospitals were more likely to adopt CPGs as compared to their counterparts 
practicing in non-academic centers. However, a finer grained resolution is required to 
truly understand the determinants of practice, and how to improve it.  
Fortunately, there is a strong tradition of theoretical and empirical work from other 
specialities outlining strategies to increase guideline adherence. Assimilating and 
extending such work presents an opportunity to test what strategies might improve 
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CPG adherence in uro-oncology. The first step in addressing a knowledge-to-practice 
gap is to understand the barriers and facilitators to best practice. Given that there are 
complex social, cultural and economic factors which influence practice, the most 
appropriate research methods for this are qualitative in nature, using ethnography, 
observations, interviews or focus groups, for instance. The findings of such studies 
enable the identified barriers and facilitators to be mapped to organisational and 
individual theories of behaviour, such as the theoretical domains framework (TDF). 
[14] Additional strategies, such as content analysis of local protocols, can provide 
context as to how international and national CPGs are interpreted and applied at the 
local level.  
Once the context and theoretical determinants of behaviour are understood then 
potential behaviour change interventions, such as those outlined in the behaviour 
change taxonomy, [15] may be selected to target organisational and behavioural 
change. Examples from other disciplines include audit and feedback to tackle 
overprescribing of antibiotics in dentistry [16], where  an increase in the adherence to 
guidelines was observed among dentists after the implementation of measures that 
included the delivery of a written behaviour change message. Conversely, a cluster 
randomized trial of a theory-based multiple behaviour change intervention that 
included outreach visits and education materials in primary care failed to improve care 
for type 2 diabetes patients [17].  
Now that implementation problems are being recognised within uro-oncology, there is 
scope to learn from other specialties, and to design ambitious and robust research to 
understand why implementation problems exist in uro-oncology and how they might 
be overcome. We owe this to urological cancer patients and their families and also to 
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healthcare funders that have to bear the cost of inappropriate non-adherence to 
guideline recommendations underpinned by high quality evidence. 
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